secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001655759-25-000081
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas cuts workforce 33%, reports positive VERITAC-2 data, removes two Phase 3 combo trials
--------------------------------------------------------------------------------

- Positive topline results from Phase 3 VERITAC-2 trial of vepdegestrant in 2L+ ER+/HER2- metastatic breast cancer; data accepted for ASCO 2025.
- Workforce reduction of ~33% across all areas; expects ~$10M in severance costs, substantially complete by end of Q2 2025.
- Removed two planned Phase 3 combination trials (first-line with atirmociclib and second-line with CDK4/6 inhibitor) from vepdegestrant plan.
- Cash, cash equivalents and marketable securities of $954.3M as of March 31, 2025; runway extended into H2 2028.
- ARV-102 Phase 1 data demonstrated blood-brain barrier penetration and >50% LRRK2 reduction in CSF at 60 mg single dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/0001655759-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/arvn-20250430.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer